Paediatrics Publications
Document Type
Article
Publication Date
2-14-2018
Journal
Clinical Epigenetics
Volume
10
First Page
21
URL with Digital Object Identifier
https://doi.org/10.1186/s13148-018-0453-8
Abstract
Background
Claes-Jensen syndrome is an X-linked inherited intellectual disability caused by mutations in the
Results
Genome-wide DNA methylation analysis of 7 male patients affected with Claes-Jensen syndrome and 56 age- and sex-matched controls identified a specific DNA methylation defect (epi-signature) in the peripheral blood of these patients, including 1769 individual CpGs and 9 genomic regions. Six healthy female carriers showed less pronounced but distinctive changes in the same regions enabling their differentiation from both patients and controls. Highly specific computational model using the most significant methylation changes demonstrated 100% accuracy in differentiating patients, carriers, and controls in the training cohort, which was confirmed on a separate cohort of patients and carriers. The 100% specificity of this unique epi-signature was further confirmed on additional 500 unaffected controls and 600 patients with intellectual disability and developmental delay, including other patient cohorts with previously described epi-signatures.
Conclusion
Peripheral blood epi-signature in Claes-Jensen syndrome can be used for molecular diagnosis and carrier identification and assist with interpretation of genetic variants of unknown clinical significance in the
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Notes
Article originally published at Clinical Epigenetics, Vol. 10.
https://doi.org/10.1186/s13148-018-0453-8
© The Author(s) 2018